From Stigma to Solutions: MBGH Panel Explores Mental Health Paradigm Shift in the Workplace
March 8th 2024The critical issue of mental health in the workplace was discussed by experts in the field at the recent Midwest Business Group on Health (MBGH) Mental Health Forum, shedding light on the growing concern surrounding alcohol use disorder and the pressing need for innovative therapies.
Read More
Real-World Study Confirms Nivolumab Plus Ipilimumab Safety in Advanced NSCLC
March 8th 2024A real-world study confirmed that the rate of adverse events associated with first-line nivolumab plus iplimumab therapy was in line with the safety profiles of other immuno-oncology and chemotherapy combination regimens.
Read More
FDA Approves Semaglutide to Prevent Heart Events in Patients With CVD and Excess Weight
March 8th 2024The FDA added another indication for semaglutide (Wegovy), expanding its use to reduce the risk of cardiovascular death, heart attack, or stroke in adults who have cardiovascular disease (CVD) and overweight or obesity.
Read More
Frailty, Depression Can Affect Social Support, Self-Management in Older Patients With COPD
March 8th 2024Self-management (SM) among older patients with chronic obstructive pulmonary disease (COPD) is moderately low, and frailty and depression may partially mediate the relationship between social support and SM in these patients.
Read More
The FDA has pushed back its approval deadline for donanemab, Eli Lilly’s experimental Alzheimer’s treatment; Cigna recently announced the launch of a program on aimed at capping annual weight-loss drug cost increases for health insurance providers and employers at 15%; a new monoclonal antibody product to protect against respiratory syncytial virus (RSV) was 90% effective at preventing children from being hospitalized.
Read More
Ruxolitinib Reduces Extent, Severity of AD and Need for Other Treatments
March 8th 2024A physician-reported outcomes survey found that physicians switched to ruxolitinib cream due to lack of effectiveness with previous atopic dermatitis (AD) treatments, and an analysis of claims data revealed the cream reduced the need for other treatments.
Read More
Zanubrutinib Plus Obinutuzumab Granted Accelerated FDA Approval for R/R Follicular Lymphoma
March 7th 2024The FDA granted accelerated approval to combination zanubrutinib and obinutuzumab for the treatment of relapsed or refractory (R/R) follicular lymphoma following 2 or more lines of therapy.
Read More
President Biden will preview his plan to more than double the size of Medicare’s new drug price negotiation program in the upcoming State of the Union address; Mexicans and Central Americans were most affected by the pandemic in terms of all-cause mortality; two Alabama fertility clinics said they expect to resume in vitro fertilization (IVF) services after a bill was passed to protect doctors.
Read More
Case Report Warns of Pneumothorax Risk in Duchenne Muscular Dystrophy
March 6th 2024The authors of this report stress the importance of awareness of COVID-19–related complications in young patients who have Duchenne muscular dystrophy, paying particular attention to a potential higher risk of respiratory infections in these patients.
Read More